Across TCGA pan-cancer cohorts, IRF1-AS1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IRF1-AS1 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher IRF1-AS1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IRF1-AS1 expression acts as an unfavorable survival marker.

BLCA and COAD are the cancer types where IRF1-AS1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.158	0.720	<.001	48	view →
COAD	OS	Median	All	0.103	0.801	<.001	24	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: IRF1-AS1 tumor-vs-normal RNA expression · all IRF1-AS1 data types